The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Adding tafasitamab to treatment with lenalidomide and rituximab improved progression-free survival in patients with relapsed or refractory follicular lymphoma.

What’s the next step for this patient with a 4-year history of low-grade follicular lymphoma and who now has worsening lymphadenopathy and needs a nap at the end of every work day? Share on ...

Most follicular lymphoma cases exhibit ... such as establishing the histologic grade and excluding a component of diffuse large B-cell lymphoma (DLBCL), she adds. PET-CT scans are helpful in ...

Part B of the study reported on an additional 142 patients with relapsed or refractory indolent lymphoma (73% FL grade 1-3a) who had received a median of 3 lines of therapy. In part B, the ...

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

The new use is the third for Kymriah (tisagenlecleucel) in the EU and offers patients with grade 1, 2 and 3A follicular lymphoma that has returned after two or more prior treatments a new ...

CRISPR Therapeutics (CRSP) presented data from the Company’s ongoing Phase 1/2 dose escalation clinical trial evaluating the safety and ...

Tafasitamab added to lenalidomide and rituximab reduced progression or death risk by 57% in relapsed/refractory follicular lymphoma patients ... with FL that was low grade and slow growing ...